SEC Comment Letter 0000000000-24-009870 to MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC.
Date: Aug. 29, 2024 · CIK: 0001938046 · Accession: 0000000000-24-009870
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281617
Letter
August 29, 2024 Jacob Cohen Chief Executive Officer Mangoceuticals, Inc. 15110 N. Dallas Parkway , Suite 600 Dallas, TX 75248 Re:Mangoceuticals, Inc. Registration Statement on Form S-1 Filed August 16, 2024 File No. 333-281617 Dear Jacob Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at 202-551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services
Show Raw Text
August 29, 2024
Jacob Cohen
Chief Executive Officer
Mangoceuticals, Inc.
15110 N. Dallas Parkway , Suite 600
Dallas, TX 75248
Re:Mangoceuticals, Inc.
Registration Statement on Form S-1
Filed August 16, 2024
File No. 333-281617
Dear Jacob Cohen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at 202-551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services